They should run them in parallel.
Potential project and start the ball rolling on distribution / wind up.
On potential project there is not a lot out there IMO that fits the bill. The company has likely already had the likes of Macquarie, Cannacord and others approach or are looking to approach with potentials. Their business models are based on fee generation so they would do a a bit of the donkey work.
You would expect if a potential project was found holders get to vote. If rejected they should be forced to wind up
In parallel the company needs to wind down its staff numbers and costs. They do not have any asset,
- If not billing GF at a premium they should be terminated bar skeleton admin / HR / Accts
- BOD numbers reduced
- No performance shares to be issued
- Start the process to sell the 1.5% income. They should get a premium.
I think it’s important that they try to get the company trading. You can wager alot of those calling for a commitment to wind up and the ASX refuses lifting suspension will be moaning in June 2025 when LLL are still sat un traded in a portfolio and gains or losses unable to be capitalised. An early wind up would require tranche 2 sold at a discount.
Don’t underestimate the opportunity cost of fees
On performance shares tough luck boys and girls. This has been a terrible outcome for shareholders. Your are lucky to have your job / get severance. Get GF to pay.
Everyone should contact the company to push for cost cutting.
- Forums
- ASX - By Stock
- Ann: MoU Signed with Mali Gov & Sale of Entire Project to Ganfeng
They should run them in parallel.Potential project and start the...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LLL (ASX) to my watchlist
(20min delay)
|
|||||
Last
50.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $605.4M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LLL (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online